The Colorado - based
biopharmaceutical company owns the worldwide rights to the drug.
Not exact matches
QS Investors LLC now
owns 75,620 shares of the
biopharmaceutical company's stock worth $ 2,358,000 after purchasing an additional 3,771 shares in the last quarter.
American International Group Inc. now
owns 51,539 shares of the
biopharmaceutical company's stock worth $ 1,607,000 after purchasing an additional 2,255 shares in the last quarter.
Zurcher Kantonalbank Zurich Cantonalbank now
owns 4,662 shares of the
biopharmaceutical company's stock worth $ 145,000 after purchasing an additional 2,698 shares in the last quarter.
Crestline Management LP now
owns 68,856 shares of the
biopharmaceutical company's stock worth $ 2,147,000 after purchasing an additional 3,437 shares in the last quarter.
Swiss National Bank now
owns 119,600 shares of the
biopharmaceutical company's stock worth $ 3,729,000 after purchasing an additional 2,800 shares in the last quarter.
Avigen, Inc. (Nasdaq: AVGN), a
biopharmaceutical company, today confirmed that BVF Acquisition LLC, a wholly
owned subsidiary of Biotechnology Value Fund, L.P. (collectively, «BVF»), had commenced an unsolicited tender offer to purchase all of the outstanding shares of Avigen's common stock that BVF does not already
own for $ 1.00 per share in cash.